NCT05450185 Filter Lifespan in Continuous Renal Replacement Therapy
| NCT ID | NCT05450185 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University Hospital Muenster |
| Condition | Critically Ill |
| Study Type | OBSERVATIONAL |
| Enrollment | 600 participants |
| Start Date | 2023-03-02 |
| Primary Completion | 2025-05 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 600 participants in total. It began in 2023-03-02 with a primary completion date of 2025-05.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The only supportive therapy for patients with AKI is renal replacement therapy (RRT). In the ICU setting, continuous RRT (CRRT) is mostly favored. In a post-hoc analysis of the RICH trial (regional citrate versus systemic heparin anticoagulation for CRRT in critically ill patient with AKI), it was shown that the filter life span is associated with an increased rate of new infection and that the type of anticoagulants did not directly affect infection rate. The mechanisms of this infection rate is unknown.
Eligibility Criteria
Inclusion Criteria: * Adult patients (age ≥18 years) * Critically ill patients with dialysis-dependent AKI * Continuous renal replacement therapy (CRRT) * Written informed consent Exclusion Criteria: * Chronic kidney disease with estimated glomerular filtration rate (eGFR)\<30ml/min/1.73m2 * Chronic dialysis dependency * Kidney transplant * (Glomerulo-)nephritis, interstitial nephritis, vasculitis * Patients on immunosuppression * Patients with chronic inflammatory diseases (e.g. arthritis, HIV, chronic hepatitis) * Persons with any kind of dependency on the investigator or employed by the sponsor or investigator
Contact & Investigator
Alexander Zarbock, MD
PRINCIPAL INVESTIGATOR
University Hospital Münster
Frequently Asked Questions
Who can join the NCT05450185 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Critically Ill. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05450185 currently recruiting?
Yes, NCT05450185 is actively recruiting participants. Contact the research team at zarbock@uni-muenster.de for enrollment information.
Where is the NCT05450185 trial being conducted?
This trial is being conducted at Innsbruck, Austria, São Paulo, Brazil, Erlangen, Germany, Mönchengladbach, Germany and 1 additional location.
Who is sponsoring the NCT05450185 clinical trial?
NCT05450185 is sponsored by University Hospital Muenster. The principal investigator is Alexander Zarbock, MD at University Hospital Münster. The trial plans to enroll 600 participants.